Cargando…

Short-Term Proton Pump Inhibitor Use and Hepatic Encephalopathy Risk in Patients with Decompensated Cirrhosis

Objective: A window period of approximately 3–6 months is usually adopted in studies that evaluate hepatic encephalopathy (HE) risk in proton pump inhibitor (PPI) users. However, HE risk after short-term PPI exposure remains unclear. We explored the effect of short-term PPI exposure using a case-cro...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuan, Yi-Chun, Huang, Kuang-Wei, Lin, Cheng-Li, Luo, Jiing-Chyuan, Kao, Chia-Hung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723586/
https://www.ncbi.nlm.nih.gov/pubmed/31349746
http://dx.doi.org/10.3390/jcm8081108
_version_ 1783448803900129280
author Kuan, Yi-Chun
Huang, Kuang-Wei
Lin, Cheng-Li
Luo, Jiing-Chyuan
Kao, Chia-Hung
author_facet Kuan, Yi-Chun
Huang, Kuang-Wei
Lin, Cheng-Li
Luo, Jiing-Chyuan
Kao, Chia-Hung
author_sort Kuan, Yi-Chun
collection PubMed
description Objective: A window period of approximately 3–6 months is usually adopted in studies that evaluate hepatic encephalopathy (HE) risk in proton pump inhibitor (PPI) users. However, HE risk after short-term PPI exposure remains unclear. We explored the effect of short-term PPI exposure using a case-crossover study design. Design: Records of patients with decompensated cirrhosis who had received an HE diagnosis were retrieved from the National Health Insurance Research Database. PPI use rates were compared for case and control with window periods of 7, 14, and 28 days. The adjusted self-matched odds ratio (OR) and 95% confidence interval (CI) from a conditional logistic regression model were used to determine the association between PPI use and HE risk. Results: Overall, 13 195 patients were analyzed. The adjusted OR for HE risk after PPI exposure was 3.13 (95% CI = 2.33–4.20) for the 7-day window, 4.77 (95% CI = 3.81–5.98) for the 14-day window, and 5.60 (95% CI = 4.63–6.78) for the 28-day window. All PPI categories, except omeprazole and pantoprazole, were associated with an increased HE risk. Irrespective of other precipitating factors, such as recent gastrointestinal bleeding or infection, PPI significantly increased HE risk. Conclusion: Short-term PPI use is significantly associated with HE in patients with decompensated cirrhosis. Physicians should use PPI in these patients for appropriate indications, and carefully monitor signs of HE even after short-term exposure. Owing to the limitations of retrospective design in the current study, further study is warranted to confirm our findings.
format Online
Article
Text
id pubmed-6723586
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67235862019-09-10 Short-Term Proton Pump Inhibitor Use and Hepatic Encephalopathy Risk in Patients with Decompensated Cirrhosis Kuan, Yi-Chun Huang, Kuang-Wei Lin, Cheng-Li Luo, Jiing-Chyuan Kao, Chia-Hung J Clin Med Article Objective: A window period of approximately 3–6 months is usually adopted in studies that evaluate hepatic encephalopathy (HE) risk in proton pump inhibitor (PPI) users. However, HE risk after short-term PPI exposure remains unclear. We explored the effect of short-term PPI exposure using a case-crossover study design. Design: Records of patients with decompensated cirrhosis who had received an HE diagnosis were retrieved from the National Health Insurance Research Database. PPI use rates were compared for case and control with window periods of 7, 14, and 28 days. The adjusted self-matched odds ratio (OR) and 95% confidence interval (CI) from a conditional logistic regression model were used to determine the association between PPI use and HE risk. Results: Overall, 13 195 patients were analyzed. The adjusted OR for HE risk after PPI exposure was 3.13 (95% CI = 2.33–4.20) for the 7-day window, 4.77 (95% CI = 3.81–5.98) for the 14-day window, and 5.60 (95% CI = 4.63–6.78) for the 28-day window. All PPI categories, except omeprazole and pantoprazole, were associated with an increased HE risk. Irrespective of other precipitating factors, such as recent gastrointestinal bleeding or infection, PPI significantly increased HE risk. Conclusion: Short-term PPI use is significantly associated with HE in patients with decompensated cirrhosis. Physicians should use PPI in these patients for appropriate indications, and carefully monitor signs of HE even after short-term exposure. Owing to the limitations of retrospective design in the current study, further study is warranted to confirm our findings. MDPI 2019-07-25 /pmc/articles/PMC6723586/ /pubmed/31349746 http://dx.doi.org/10.3390/jcm8081108 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kuan, Yi-Chun
Huang, Kuang-Wei
Lin, Cheng-Li
Luo, Jiing-Chyuan
Kao, Chia-Hung
Short-Term Proton Pump Inhibitor Use and Hepatic Encephalopathy Risk in Patients with Decompensated Cirrhosis
title Short-Term Proton Pump Inhibitor Use and Hepatic Encephalopathy Risk in Patients with Decompensated Cirrhosis
title_full Short-Term Proton Pump Inhibitor Use and Hepatic Encephalopathy Risk in Patients with Decompensated Cirrhosis
title_fullStr Short-Term Proton Pump Inhibitor Use and Hepatic Encephalopathy Risk in Patients with Decompensated Cirrhosis
title_full_unstemmed Short-Term Proton Pump Inhibitor Use and Hepatic Encephalopathy Risk in Patients with Decompensated Cirrhosis
title_short Short-Term Proton Pump Inhibitor Use and Hepatic Encephalopathy Risk in Patients with Decompensated Cirrhosis
title_sort short-term proton pump inhibitor use and hepatic encephalopathy risk in patients with decompensated cirrhosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723586/
https://www.ncbi.nlm.nih.gov/pubmed/31349746
http://dx.doi.org/10.3390/jcm8081108
work_keys_str_mv AT kuanyichun shorttermprotonpumpinhibitoruseandhepaticencephalopathyriskinpatientswithdecompensatedcirrhosis
AT huangkuangwei shorttermprotonpumpinhibitoruseandhepaticencephalopathyriskinpatientswithdecompensatedcirrhosis
AT linchengli shorttermprotonpumpinhibitoruseandhepaticencephalopathyriskinpatientswithdecompensatedcirrhosis
AT luojiingchyuan shorttermprotonpumpinhibitoruseandhepaticencephalopathyriskinpatientswithdecompensatedcirrhosis
AT kaochiahung shorttermprotonpumpinhibitoruseandhepaticencephalopathyriskinpatientswithdecompensatedcirrhosis